Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.
- Conditions
- - ALL CD52 positive - Age >18 - Unresponsive to the standard therapy - First or following relapse, also after transplant, and no more eligible to the treatment with other therapies, either conventional or transplantological.MedDRA version: 6.1Level: HLTClassification code 10024290
- Registration Number
- EUCTR2004-001739-53-IT
- Lead Sponsor
- G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method